Clinical Trial Update: Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of famitinib and SHR6390 with endocrine therapy for HR-positive, HER2-negative metastatic breast cancer ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Famitinib (Famitinib)
• SHR6390 (SHR6390)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED